STELIOS PAPADOPOULOS
CIK 1202098 · last filed 2026-05-29
STELIOS PAPADOPOULOS is a corporate insider who has filed 110 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for EXEL, was dated May 29, 2026. Across all open-market trades the lifetime net is −$16.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $69.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$69.62M
7
110
-$16.51M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EXEL | Director | 1,197,595 | $53.13 | $63.63M | -$15.23M | 38 | 2026-05-29 |
| OVID | Director | 217,578 | $2.30 | $500.4K | $0 | 3 | 2026-04-09 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 0 | $8.16 | $0 | $2.77M | 34 | 2025-06-27 |
| BIIB | Director | 27,470 | $200.05 | $5.50M | -$5.43M | 16 | 2022-06-17 |
| Eucrates Biomedical Acquisition Corp. (EUCRU) Delisted | Director | 2,619,906 | $10.02 | $26.25M | $0 | 1 | 2020-11-27 |
| BG Medicine, Inc. (BGMD) Delisted | Director | 1,187,713 | — | — | $1.02M | 7 | 2013-06-14 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | 814,206 | — | — | $369.5K | 10 | 2011-05-27 |
Recent Filings
110 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-29 | EXEL | Grant (A) | +8,367 | $0 | EDGAR |
| 2026-04-09 | OVID | Grant (A) | +17,578 | $45.0K | EDGAR |
| 2026-03-02 | OVID | Grant (A) | — | $0 | EDGAR |
| 2025-11-13 | EXEL | Sell (S) | −100,000 | -$4.36M | EDGAR |
| 2025-06-27 | Regulus Therapeutics Inc. (RGLS) Delisted | Mixed | −1,040,888 | $0 | EDGAR |
| 2025-05-30 | EXEL | Grant (A) | +9,812 | $0 | EDGAR |
| 2025-05-16 | EXEL | Mixed | — | -$885.8K | EDGAR |
| 2025-04-30 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | +62,500 | $0 | EDGAR |
| 2025-03-04 | OVID | Grant (A) | — | $0 | EDGAR |
| 2024-06-04 | EXEL | Grant (A) | +18,838 | $0 | EDGAR |